R3
Platform
Launch Engine
A New Era of Enzymatic Synthesis

Begin Your Discovery with
Enzymatic Precision

Embark on a faster journey to the clinic. R3 bypasses traditional fermentation to produce bright, pure, high-fidelity plasmid DNA—scaling seamlessly for your next big breakthrough.

Our Core Pillars

Next-Gen Vector Engineering

High-Throughput Synthesis

Parallel enzymatic reaction chambers capable of synthesizing high-fidelity variants without host-cell toxicity constraints, speeding up your workflow.

Scalable Production (RUO to cGMP)

Linear yield metrics allow direct, effortless transition from milligram screening preps to gram-scale clinical trial lots.

Sequence Optimization

Algorithmic sequence modification engineered to resolve unstable ITRs and high-GC structural bottlenecks for smooth sailing.

Fast & Flexible

Research Use Only (RUO)

Accelerate your screening phases with our rapid-turnaround plasmid preps. Synthesized with bright, proof-reading polymerases, we ensure unmatched sequence fidelity to keep your research moving forward.

< 5 Days
Turnaround Time
99.99%
Proofreading Fidelity
Peace of Mind

Pre-clinical & cGMP Manufacturing

1

Zero Host Contamination

100% cell-free enzymatic synthesis beautifully eliminates bacterial genomic DNA risks.

2

Analytical Testing

Multi-stage Sanger sequencing, restriction digest mapping, and HPLC purity profiling.

3

Endotoxin Controls

Ultra-low endotoxin thresholds (<0.005 EU/mg) strictly certified for safe in vivo trials.

4

Regulatory Packages

Automated, pristine generation of Certificates of Analysis (CoA) and IND filing dossiers.

Frameworks

Available Libraries

Pre-validated construct architectures designed to brighten up your cell and gene therapy applications.

AAV Vector Suite

Helper-free Rep/Cap plasmids designed for high packaging efficiency and joyful low empty-capsid ratios.

Serotypes: AAV1 - AAV9, Rh10

mRNA Templates

High-yield linear template vectors with standardized poly(A) tail lengths, ensuring smooth IVT mRNA synthesis.

Features: Minimal Secondary Folding

CRISPR/Cas9 Suites

Single and multiplex gRNA backbone architectures crafted for highly efficient knockout and knock-in editing.

Compatible: SpCas9, SaCas9, Cas12a

Dynamic Quoting Engine

Select manufacturing specs for instant, happy cost estimates.

Target Scale 100 mg
1 mg (Discovery) 1 Gram (cGMP)
Est. Investment
$3,500
Delivery Lead Time
5 Business Days

Say Hello!

Consult directly with our friendly vector engineering scientists.